Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score

Supportive Care in Cancer

Volumn 10, Issue 8, 2002, Pages 624-629

  Grunberg, Steven M ^a   Srivastava, Alka ^a   Grunberg, Kelly J ^b   Weeks, Jane ^c  

^a UNIVERSITY OF VERMONT   (United States)

^b Dana Farber Cancer Institute ^*  (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Nausea and vomiting; Patient preference; Standard Gamble; Utility

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EXERCISE; HUMAN; OUTCOMES RESEARCH; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; TASTE PREFERENCE; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; ATTITUDE TO DEATH; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERVIEWS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PATIENT SIMULATION; QUALITY OF LIFE; RISK-TAKING; SEX FACTORS; SURVIVORS; VOMITING;

EID: 0036940871     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-002-0381-0     Document Type: Article

References (20)

1. Coates A, Abraham S, Kaye SB, et al “1983” On the receiving end - Patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208
2. Earle CC, Chapman RH, Baker CS, et al “2000” Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18:3302-3317
3. Furlong W, Feeny D, Torrance GW, et al “1990” Guide to Design and Development of Health-State Utility Instrumentation. “CHEPA Working Paper Series #90-9” McMaster University, Hamilton, Ont
4. Gold MR, Siegel JE, Russell LB, et al “1996” Cost-effectiveness in health and medicine. Oxford University Press, New York
5. Goldhirsch A, Gelber RD, Simes RJ, et al “1989” Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7:36-44
6. Griffin AM, Butow PN, Coates AS, et al “1996” On the receiving end. V. Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189-195
7. Grunberg SM “2000” Determination of Utilities for Control of Chemotherapy-Induced Nausea or Vomiting. “CALGB 309801” CALGB, Chicago
8. Grunberg SM, Hesketh PJ “1993” Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796
9. Grunberg SM, Boutin N, Ireland A, et al “1996” Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 4:435-439
10. Hristova L, Hakama M “1997” Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 36 [Suppl 9]:1-60
11. Krahn MD, Mahoney JE, Eckman MH, et al “1994” Screening for prostate cancer: A decision analytic view. JAMA 272:773-780
12. Lindley CM, Hirsch JD, O'Neill CV, et al “1992” Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340
13. Read JL, Quinn RJ, Berwick DM, et al “1984” Preferences for health outcomes - Comparison of assessment methods. Med Decis Making 4:315-329
14. Robinson R “1993” Cost-utility analysis. BMJ 307:859-862
15. Sharma S, Brown GC, Brown MM, et al “2000” Converting visual acuity to utilities. Can J Ophthalmol 35:267-272
16. Souchek J, Stacks JU, Brody B, et al “2000” A trial for comparing methods for eliciting treatment preferences from men with advanced prostate cancer. Results from the initial visit. Med Care 38:1040-1050
17. Sutherland HJ, Dunn V, Boyd NF “1983” Measurement of values for states of health with linear analog scales. Med Decis Making 3:477-487
18. Weeks J “1995” Measurement of utilities and quality-adjusted survival. Oncology 9:67-70
19. Weeks JC “1995” Special issues that arise in applying techniques of economic analysis to evaluation of cancer therapies. Monogr Natl Cancer Inst 19:11-12
20. Williams C, Coyle D, Gray A, et al “1995” European School of Oncology advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" on cost-effectiveness in cancer care. Eur J Cancer [A] 31:1410-1424